ライフサイエンスコーパス: tuberculin

1 ced in the thigh by intradermal injection of tuberculin.

2 nses to purified protein derivative (PPD) of tuberculin.

3 e of the broad antigenic cross-reactivity of tuberculin.

4 d as the new U.S. reference standard for PPD tuberculin.

5 an did PBMC from healthy persons reactive to tuberculin.

6 r induced skin test reactivity to commercial tuberculin.

7 t that measures an immunological response to tuberculin.

8 ically predisposed to react less strongly to tuberculin.

9 yed hypersensitivity response to intradermal tuberculin also demonstrates significant genetic varianc

10 n evaluation that included skin testing with tuberculin and at least two other antigens (mumps, tetan

11 mon antigens: purified protein derivative of tuberculin and Candida albicans.

12 ive (PPD) response < 5 mm completed two-step tuberculin and candida skin testing.

13 esponse to purified protein derivative (PPD) tuberculin and mumps antigen, CD4 T-lymphocyte counts, a

14 f the IFN-gamma and IL-4 responses to bovine tuberculin and to ESAT-6 following experimental intratra

15 by the delayed hypersensitivity skin test to tuberculin, and antigen-induced lymphoproliferation in v

16 tuberculosis requires the development of new tuberculins consisting of antigens specific to M. tuberc

17 of pulmonary tuberculosis incidence based on tuberculin conversion rates may be invalid in such areas

18 upation was strongly associated with risk of tuberculin conversion.

19 The rate of tuberculosis was highest among tuberculin converters (5.4 cases per 100 person-years [C

20 se in whole blood following stimulation with tuberculin has the potential to detect tuberculosis infe

21 ions as well as complex Ag mixtures, such as tuberculin, mycobacterial lysates, and culture supernata

22 43, p < 0.0001; purified protein derivative tuberculin, n = 6, p = 0.0299).

23 in-positive asymptomatic subjects, and in 14 tuberculin-negative control subjects.

24 ositive individuals than in blood samples of tuberculin-negative individuals (P=.005).

25 e ability of healthy tuberculin-positive and tuberculin-negative individuals to restrict mycobacteria

26 Six healthy tuberculin-negative volunteers served as subjects.

27 rotein derivative of M. tuberculosis: 60% of tuberculin-nonreactive patients were of this type.

28 iagnostic specificity due to the presence in tuberculin of antigens shared by many mycobacterial spec

29 trials to evaluate its potential to replace tuberculin, or purified protein derivative, as the rapid

30 The ability of healthy tuberculin-positive and tuberculin-negative individuals

31 ne production in 20 patients with PTB, in 20 tuberculin-positive asymptomatic subjects, and in 14 tub

32 test responses in 78% of naturally infected tuberculin-positive cattle.

33 Cambodian patients with pulmonary TB and 106 tuberculin-positive control subjects.

34 was significantly lower in blood samples of tuberculin-positive individuals than in blood samples of

35 ron response in vitro using whole blood from tuberculin-positive reactor (TB reactor) cattle.

36 Since 1951, the tuberculin PPD-S1 has been used to standardize commercia

37 ) response to purified protein derivative of tuberculin (PPD), the expression of cellular IFN-gamma a

38 Bovine tuberculin (PPDB) induced greater IL-22 and IL-17A produ

39 perienced paradoxical responses and received tuberculin purified protein derivative (PPD) in Group 1

40 To investigate this, we injected tuberculin purified protein derivative (PPD) into the sk

41 we used a human experimental system whereby tuberculin purified protein derivative (PPD) was injecte

42 tients by their lack of dermal reactivity to tuberculin purified protein derivative (PPD).

43 However, 48 h after tuberculin purified protein derivative administration in

44 were investigated by T cell proliferation to tuberculin purified protein derivative or allogeneic res

45 ited the recall antigen response by PBMCs to tuberculin purified protein derivative.

46 Tuberculin (purified protein derivative [PPD])-induced l

47 creted antigenic target 6 (ESAT6) protein or tuberculin (purified protein derivative) with interferon

48 Compared with those in tuberculin (purified protein derivative)-negative contro

49 We herein report a giant tuberculin reaction associated with the homeopathic drug

50 feron production by lymphocytes from healthy tuberculin reactors and was recognized by monoclonal ant

51 CD4(+) cells from healthy tuberculin reactors produced IL-17 in response to autolo

52 Depletion of NK cells from PBMC of healthy tuberculin reactors reduced the frequency of M. tubercul

53 peripheral blood CD8(+) T cells from healthy tuberculin reactors that were cultured with Mycobacteriu

54 ulated peripheral blood T cells from healthy tuberculin reactors, recombinant IL-10 and TGF-beta redu

55 cell response to M. tuberculosis in healthy tuberculin reactors.

56 in nuclear extracts of T cells from healthy tuberculin reactors.

57 tuberculosis patients, compared with healthy tuberculin reactors.

58 PBMC) from tuberculosis patients and healthy tuberculin reactors.

59 ression in tuberculosis patients and healthy tuberculin reactors.

60 nd protein than CD14+ monocytes from healthy tuberculin reactors.

61 Positive tuberculin responses predicted a lower incidence of asth

62 , such as thymic atrophy, impaired cutaneous tuberculin responses, and reduced T cell mitogenesis in

63 tle despite them being sensitized for strong tuberculin responses.

64 test results, and 5% to 10% have a negative tuberculin result but have a positive reaction to anothe

65 ention Coalition conducted a community-based tuberculin screening and isoniazid preventive therapy pr

66 he major limitations of this community-based tuberculin screening and preventive therapy project were

67 Tuberculin screening of socioeconomically disadvantaged

68 Widespread tuberculin screening of students yielded a low prevalenc

69 the use of limited public health resources, tuberculin screening should target students at high risk

70 Overall, 378 schools (61%) required tuberculin screening; it was required for all new studen

71 Tuberculin shock due to inoculation of Mycobacterium tub

72 serum tumor necrosis factor alpha and causes tuberculin shock in infected guinea pigs characterized b

73 results point to the possible occurrence of tuberculin shock in sensitive individuals inoculated wit

74 , a pathological observation consistent with tuberculin shock.

75 the single intradermal cervical comparative tuberculin (SICCT) test and that were identified from da

76 d by the Single Intradermal Comparative Skin Tuberculin (SICST), as a preliminary screen for the pres

77 aradoxical response associated with enhanced tuberculin skin reactivity may occur after the initiatio

78 erapy (ART)-naive HIV-infected patients with tuberculin skin test >/=5 mm were recruited from Khayeli

79 th latent tuberculosis infection by positive tuberculin skin test (>5 mm) were prospectively enrolled

80 om we tested, 56 (20 percent) had a positive tuberculin skin test (induration of at least 10 mm), inc

81 e tested for tuberculosis infection with the tuberculin skin test (n = 1389) and QuantiFERON assay (n

82 [OR], 7.90; P < .001), and baseline positive tuberculin skin test (OR, 2.21; P = .03); BCG vaccinatio

83 mma release assays correlate better than the tuberculin skin test (P = 0.0011).

84 of infected animals, based primarily on the tuberculin skin test (PPD).

85 release assay was compared with the standard tuberculin skin test (TST) among 467 intravenous drug us

86 erferon gamma release assays (IGRAs) and the tuberculin skin test (TST) among PLWH are lacking.

87 All persons with a positive tuberculin skin test (TST) and anergic individuals who h

88 trimester and at delivery for LTBI using the tuberculin skin test (TST) and IFN-gamma release assay (

89 A cost analysis of combining a tuberculin skin test (TST) and the QuantiFERON-TB Gold t

90 ld-in-tube (QGIT) antepartum and by QGIT and tuberculin skin test (TST) at delivery and postpartum.

91 (IFNG) rs1143627 (IL1B) as risk factors for tuberculin skin test (TST) conversion or development of

92 with a household member with TB or a recent tuberculin skin test (TST) conversion were included in t

93 d the effect of vitamin D supplementation on tuberculin skin test (TST) conversion.

94 QFT-GIT) is considered an alternative to the tuberculin skin test (TST) for the diagnosis of tubercul

95 The tuberculin skin test (TST) has a poor sensitivity in thi

96 of QuantiFERON-TB Gold In-Tube (QFT-GIT) and tuberculin skin test (TST) has not been compared in a US

97 t clearly suggest that IGRAs are better than tuberculin skin test (TST) in identifying individuals wi

98 The tuberculin skin test (TST) is the primary method for dia

99 The tuberculin skin test (TST) is widely used but suffers po

100 The tuberculin skin test (TST) measures the intensity of ant

101 N Gold-in-Tube (QFT-GIT), T-SPOT.TB, and the tuberculin skin test (TST) might improve prediction of i

102 n-born individuals aged 12-50 years who were tuberculin skin test (TST) negative and eligible for BCG

103 ied in the same family sample, that controls tuberculin skin test (TST) negativity per se, that is, T

104 children and adults with LTBI have positive tuberculin skin test (TST) or interferon gamma release a

105 ium bovis bacillus Calmette-Guerin (BCG) nor tuberculin skin test (TST) positive (group A controls),

106 The development of tuberculin skin test (TST) positivity following infectio

107 contagious tuberculosis case display lack of tuberculin skin test (TST) reactivity.

108 for only household contacts with a positive tuberculin skin test (TST) result.

109 erican or other nonwhite ethnicity, positive tuberculin skin test (TST) results, age, and education;

110 ional health programs that switched from the tuberculin skin test (TST) to IFN-gamma release assays f

111 ar microscopy, Xpert MTB/RIF (Cepheid Inc.), tuberculin skin test (TST), and chest radiography.

112 The current method, the tuberculin skin test (TST), has poor specificity because

113 ients with tuberculosis who had a diagnostic tuberculin skin test (TST), only 18 (69%) were positive

114 esence of latent tuberculosis infection: the tuberculin skin test (TST), QuantiFERON-TB Gold (QFT-G),

115 ree commercially approved tests, namely, the tuberculin skin test (TST), the Quantiferon-TB Gold in-t

116 ma) assays are promising alternatives to the tuberculin skin test (TST), their serial testing perform

117 latent tuberculosis infection relies on the tuberculin skin test (TST), which has many drawbacks.

118 confirmed pulmonary tuberculosis (cases), 47 tuberculin skin test (TST)-positive controls, and 39 TST

119 ntil recently, diagnosis has relied upon the tuberculin skin test (TST).

120 LTBI that has potential advantages over the tuberculin skin test (TST).

121 -Tube (QFT-GIT), T-SPOT.TB (T-SPOT), and the tuberculin skin test (TST).

122 posed to offer improved specificity over the tuberculin skin test (TST).

123 agnostic test; 2) enroll based on a positive tuberculin skin test (TST); 3) enroll based on a positiv

124 over 3 consecutive periods: first, a 2-step tuberculin skin test (TST); second, a 2-step TST plus Qu

125 dentified as controlling the response to the tuberculin skin test (TST1 and TST2) and the production

126 ccording to their Mtb infection status using Tuberculin skin test (TST; cohort 1) or QuantiFERON (QFT

127 ding to their Mtb infection status using the tuberculin skin test (TST; cohort 1) or QuantiFERON (QFT

128 bacteriologies, TB infection (TBI) testing (tuberculin skin test [TST] and interferon gamma release

129 A positive tuberculin skin test alone among clinical laboratory fin

130 To determine the prevalence of a positive tuberculin skin test among economically disadvantaged yo

131 nt among persons with recent conversion of a tuberculin skin test and among most persons younger than

132 osis and history of tuberculosis then used a tuberculin skin test and an interferon-gamma release ass

133 tigated for latent tuberculosis infection by tuberculin skin test and at least one IFN-gamma release

134 ersons with induration of 10 mm or more on a tuberculin skin test and either human immunodeficiency v

135 e community-based study assessing use of the tuberculin skin test and IFN-gamma release assays among

136 is doses, suggesting that diagnostic assays (tuberculin skin test and IFN-gamma test) can detect catt

137 core predicted tuberculosis independently of tuberculin skin test and index-case drug sensitivity res

138 otifications in young children and trends in tuberculin skin test and interferon gamma-release assays

139 Mtb infection is identified using the tuberculin skin test and interferon-gamma (IFN-gamma) re

140 ersus low and high aerosols had differential tuberculin skin test and interferon-gamma release assay

141 were recruited; all participants underwent a tuberculin skin test and QuantiFERON-TB Gold assay.

142 Among children with no documented contact, tuberculin skin test and QuantiFERON-TB Gold In-Tube pos

143 tionship between the intradermal comparative tuberculin skin test and serum immunoglobulin G [IgG] re

144 Overall agreement between the tuberculin skin test and the QFT test was moderate (81.0

145 Rates of positivity for the tuberculin skin test and the QFT test were low in study

146 umber of contacts undergoing evaluation (ie, tuberculin skin test and/or chest radiograph) per preval

147 Immune-based TB screening (tuberculin skin test and/or interferon-gamma release ass

148 Immune-based TB screening (tuberculin skin test and/or interferon-gamma release ass

149 Giant reactions to the tuberculin skin test are extremely rare and have been pr

150 monkeys were successfully infected, based on tuberculin skin test conversion and peripheral immune re

151 The tuberculin skin test conversion rates (>6 mm) of the two

152 al health laboratories or the annual risk of tuberculin skin test conversion.

153 fined as the propensity of isolates to cause tuberculin skin test conversions among named contacts, a

154 The tuberculin skin test currently used to diagnose infectio

155 that either IGRA was more sensitive than the tuberculin skin test for active tuberculosis diagnosis.

156 they may offer advantages compared with the tuberculin skin test for identifying TB infection, and i

157 terferon release assays are preferred to the tuberculin skin test for screening certain at-risk popul

158 ly used as an alternative to the traditional tuberculin skin test for the diagnosis of latent Mycobac

159 period, 18 liver transplant candidates with tuberculin skin test greater than 5 mm or recent convers

160 The tuberculin skin test has been used for the diagnosis of

161 ansplant recipients who test positive on the tuberculin skin test has not been defined.

162 s that are most likely to predict a positive tuberculin skin test in contacts of tuberculosis cases.

163 ailable data, IGRAs have advantages over the tuberculin skin test in specific patient populations and

164 999-2000, NHANES assessed LTBI (defined as a tuberculin skin test measurement >/=10 mm) in participan

165 findings showing that the performance of the tuberculin skin test might be affected by various factor

166 ow- and middle-income countries, neither the tuberculin skin test nor IGRAs have value for active tub

167 system was developed, including reaction to tuberculin skin test of the contacts, as well as smear-p

168 Inaccuracy of the tuberculin skin test often reflects a low diagnostic spe

169 etween 5 and 17 years with either a positive tuberculin skin test or an immunocompromising condition,

170 restricted to patients who were positive on tuberculin skin test or interferon gamma release assay (

171 rate or high incidence areas irrespective of tuberculin skin test or interferon gamma release assay s

172 baseline and follow-up visits, (2) positive tuberculin skin test or QuantiFERON-TB Gold (Cellestis I

173 bservational studies that applied either the tuberculin skin test or the interferon gamma release ass

174 Participants who were tuberculin skin test positive (ie, >/=5 mm induration) a

175 cebo or alternative regimen in HIV-positive, tuberculin skin test positive individuals.

176 ection, and chiefly benefited those who were tuberculin skin test positive.

177 lowed 6 weeks later by a late-winter peak in tuberculin skin test positivity and 12 weeks after that

178 0.35-0.7 IU/ml, and greater than 0.7 IU/ml, tuberculin skin test positivity results were 15%, 53%, 6

179 False-positive tuberculin skin test reactions associated with reactivit

180 prevalence of latent tuberculosis infection (tuberculin skin test reactivity >/=10 mm), human immunod

181 Children younger than 6 yr of age who had a tuberculin skin test read at public health clinics in ar

182 One or both commercial tuberculin skin test reagents (Aplisol and Tubersol) may

183 a2(+) T cell response was independent of the tuberculin skin test response.

184 re found to significantly predict a positive tuberculin skin test result among contacts of an active

185 labeling change, 34 patients with a negative tuberculin skin test result before initiation of inflixi

186 A negative tuberculin skin test result does not exclude either late

187 result was shown by 5.5% of children with a tuberculin skin test result less than 5 mm, by 14.8% if

188 dict contacts most likely to have a positive tuberculin skin test result.

189 is commonly used to help interpret negative tuberculin skin test results, the validity of this appro

190 puses has prompted some schools to institute tuberculin skin test screening of students, but this scr

191 between sarcoidosis and tuberculosis include tuberculin skin test status, the presence of ocular surf

192 igen 85 (Ag85) proteins independent of their tuberculin skin test status.

193 ollowing M. bovis infection, the comparative tuberculin skin test strongly boosted IgG, IgG1, and IgG

194 cial for effective tuberculosis control, but tuberculin skin test surveys have major limitations, inc

195 roughout the study, and the responses to the tuberculin skin test were assessed at two times.

196 r than 5 mm or recent conversion to positive tuberculin skin test were identified and received isonia

197 can adults with HIV infection and a positive tuberculin skin test who were not taking antiretroviral

198 All subjects with a positive tuberculin skin test without prior active tuberculosis w

199 erformed in preference to T-SPOT.TB (and the tuberculin skin test) for diagnosing tuberculous uveitis

200 ative disease by IFN-gamma release assay and tuberculin skin test, 'resisting' development of classic

201 sted negative by IFN-gamma release assay and tuberculin skin test, 'resisting' development of classic

202 ative disease by IFN-gamma release assay and tuberculin skin test, 'resisting' development of classic

203 ning, 27% had an initial but no postexposure tuberculin skin test, 12% were not screened, and 6% had

204 B Gold In-Tube test, (2) T-SPOT.TB test, (3) tuberculin skin test, and (4) Battey skin test using pur

205 We performed clinical assessment, tuberculin skin test, and chest radiography in all eligi

206 apy against tuberculosis without obtaining a tuberculin skin test, but duration of prophylaxis is res

207 ositivity rates were lower compared with the tuberculin skin test, likely reflecting the higher speci

208 ites located across the United States with a tuberculin skin test, QuantiFERON (R) Gold In-Tube test,

209 cyte sedimentation rate, C-reactive protein, tuberculin skin test, syphilis serology, and chest radio

210 The tuberculin skin test, the traditional assay for diagnosi

211 s was reported among clients with a positive tuberculin skin test, thereby preventing as much as 95%

212 n (BCG) all interfere with the action of the tuberculin skin test, which is used to determine if anim

213 atent TB-infected subjects, TB patients, and tuberculin skin test-negative donors stimulated with the

214 heir tuberculin skin tests, and from healthy tuberculin skin test-negative individuals or individuals

215 on for tuberculous infection who were either tuberculin skin test-negative or positive, the specifici

216 0.80, p=0.02), whereas participants who were tuberculin skin test-negative received no significant be

217 duals and patients with active TB but not by tuberculin skin test-negative subjects.

218 h bacillus Calmette-Guerin (BCG) in healthy, tuberculin skin test-positive (>/=15-mm induration), HIV

219 Cell subsets from tuberculosis cases and tuberculin skin test-positive (TST(+)) and TST-negative

220 For this analysis we used naturally exposed tuberculin skin test-positive field reactor cattle, unin

221 smear and culture-positive tuberculosis and tuberculin skin test-positive healthy control individual

222 ompared between both M. tuberculosis-exposed tuberculin skin test-positive healthy household contacts

223 d by circulating CD8+ CTLs from both healthy tuberculin skin test-positive individuals and patients w

224 nts with active tuberculosis (TB) as well as tuberculin skin test-positive individuals who had no his

225 cer, and in peripheral blood of asymptomatic tuberculin skin test-positive individuals with recent (h

226 Stimulation of T cells from healthy tuberculin skin test-positive persons with live M. tuber

227 (+) T lymphocytes were analyzed from healthy tuberculin skin test-positive persons.

228 sponses toward IVE-TB Ags, albeit lower than tuberculin skin test-positive, ESAT6/CFP10-responsive in

229 roteins were recognized by immune cells from tuberculin skin test-positive, ESAT6/CFP10-responsive in

230 skin test reaction size were associated with tuberculin skin test-positive, IFN-gamma release assay-n

231 f reactivity to tuberculosis proteins in the tuberculin skin test.

232 er who have induration of 10 mm or more on a tuberculin skin test.

233 f tuberculosis among persons with a positive tuberculin skin test.

234 py and have induration of 15 mm or more on a tuberculin skin test.

235 contacts are most likely to have a positive tuberculin skin test.

236 had a history of prior TB or prior positive tuberculin skin test.

237 h a history of extended travel should have a tuberculin skin test.

238 T-SPOT.TB, QuantiFERON-TB Gold In-Tube, and tuberculin skin test.

239 a release assays (IGRAs) are alternatives to tuberculin skin testing (TST) for diagnosis of latent tu

240 symptom-based screening as a replacement for tuberculin skin testing (TST) to simplify contact evalua

241 To determine the value of two-step tuberculin skin testing (TTST) as a method of increasing

242 ntified, compared with $32,100 per case with tuberculin skin testing and $54,100 per case with sympto

243 eness of four strategies: no intervention or tuberculin skin testing followed by treatment with isoni

244 nce of tuberculous infection, measured using tuberculin skin testing in a cohort of schoolchildren, a

245 as a method of increasing the sensitivity of tuberculin skin testing in HIV-infected persons, a conse

246 Screening for latent tuberculosis with tuberculin skin testing is effective, and compliance wit

247 Tuberculin skin testing is used to screen for latent inf

248 Contacts underwent tuberculin skin testing to determine tuberculosis infect

249 workers, the 11 (15%) who had conversion on tuberculin skin testing were no more likely than those w

250 tuberculosis infection was measured through tuberculin skin testing, and relative risks were calcula

251 sis of tuberculosis (TB) in cattle relies on tuberculin skin testing, and when combined with the slau

252 Analysis of M. tuberculosis isolates, tuberculin skin testing, assessment of exposure, and ass

253 Screening was verbal, and proceeded to tuberculin skin testing, if appropriate.

254 hest radiography, molecular diagnostics, and tuberculin skin testing.

255 is of clinical and radiological findings and tuberculin skin testing.

256 fection, identified by persistently negative tuberculin skin tests (TST) and interferon-gamma release

257 ple living with HIV (PLWH) who have positive tuberculin skin tests (TST) benefit from isoniazid preve

258 ts screened using a TB risk assessment tool, tuberculin skin tests (TST) placed and read, TST results

259 Tuberculin skin tests (TSTs) and QFTs were performed at

260 HIV-infected patients who had positive tuberculin skin tests (TSTs) were followed until tubercu

261 -eight percent of eligible contacts received tuberculin skin tests (TSTs).

262 Tuberculin skin tests and interferon-gamma release assay

263 erculosis in SOT candidates/recipients using tuberculin skin tests and interferon-gamma release assay

264 rotein derivative (PPD) in Group 1 had their tuberculin skin tests convert from negative to strongly

265 LTBI was ascertained from tuberculin skin tests given during the 1999-2000 Nationa

266 idence of previous tuberculosis and positive tuberculin skin tests who have not had prior treatment.

267 Of eligible clients, 99% received tuberculin skin tests, 96% received a medical examinatio

268 berculosis documented by conversion of their tuberculin skin tests, and from healthy tuberculin skin

269 ts to complete a questionnaire and performed tuberculin skin tests.

270 00 cells/mm3 or less and positive results on tuberculin skin tests.

271 iables associated with positivity of QFT and tuberculin skin tests.

272 We conducted a tuberculin skin-test survey in 5,119 preschool children

273 the estimates derived from population-level tuberculin skin-test surveys using traditional cutoff me

274 ression analyses of the tuberculosis and the tuberculin-skin test positive groups revealed, on the ba

275 losis patients and healthy control subjects (tuberculin-skin test positive or general population) wer

276 y diagnosed pulmonary tuberculosis (TB), and tuberculin-skin-test-reactive healthy control subjects.

277 commercial PPD reagents and perform special tuberculin surveys.

278 Tuberculin syringes yielded viable virus from 96%, 71%,

279 es and high void volume (32 microL) for 1-mL tuberculin syringes.

280 es where it is not economical to implement a tuberculin test and slaughter control program.

281 ctive tuberculosis, 10% to 20% have negative tuberculin test results, and 5% to 10% have a negative t

282 the single intradermal comparative cervical tuberculin test used to diagnose BTB is reduced in cattl

283 say for bovine tuberculosis, the intradermal tuberculin test, has low accuracy.

284 2% of nasal swabs (n = 121) from cattle from tuberculin test-positive herds.

285 ssociated with the reaction of cattle to the tuberculin test.

286 1; 95% CI, .01-.77) and children stringently tuberculin tested (RR, 0.08; 95% CI, .03-.25).

287 on appeared greatest in children stringently tuberculin tested, to try to exclude prior infection wit

288 Targeted tuberculin testing and LTBI treatment is feasible and li

289 ugh medical history regarding TB, as well as tuberculin testing and radiographic examination (if indi

290 nergy testing has been used as an adjunct to tuberculin testing for assessing M. tuberculosis (MTB) i

291 These results show that repeat tuberculin testing in this BCG-vaccinated population cau

292 Neither anergy testing nor tuberculin testing obviates the need for microbiologic e

293 ain can be attributed to infection missed by tuberculin testing.

294 ung pathology without sensitizing animals to tuberculin testing.

295 A total of 7,246 persons participated in tuberculin testing; 4,701 (65%) adhered with skin test r

296 Twenty-six subjects received two tuberculin tests (both 10 units) administered by the Man

297 tudy was to investigate the effect of repeat tuberculin tests at 1 wk in BCG-vaccinated healthy subje

298 s a prime candidate for a component of a new tuberculin that will allow discrimination by a skin test

299 Reactivity to tuberculin, the basis of diagnostic testing, is dependen

300 ersensitivity (DTH) responses to intradermal tuberculin were significantly lower, and peritoneal macr